Skip to content

Emma M. Bonniwell

3 papers in the library · 221 citations · publishing 2022-2025

Papers

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential.

Nat Commun December 15, 2023 Jason Wallach, Andrew B. Cao, Maggie M. Calkins et al. 153 citations

Serotonergic psychedelics show therapeutic potential, but the specific roles of 5-HT2A receptor signaling pathways are unclear. Researchers developed selective ligands with varying Gq efficacies, including β-arrestin-biased ones. In male mice, 5-HT2A-Gq recruitment efficacy, not β-arrestin2 recruitment, predicted psychedelic potential measured by head-twitch response magnitude. Disrupting Gq-PLC signaling reduced this response, and a threshold Gq activation level was needed for psychedelic-like effects, explaining why partial agonists like lisuride are non-psychedelic. β-arrestin-biased agonists blocked psychedelic effects and caused receptor downregulation and tachyphylaxis. Fine-tuning 5-HT2A Gq-signaling enables development of non-psychedelic 5-HT2A agonists.

Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs

ACS Chemical Neuroscience December 15, 2022 Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano et al. 65 citations

Ariadne, a non-hallucinogenic analog of the hallucinogen DOM, demonstrates significant therapeutic potential in treating various conditions. In clinical trials, Ariadne led to rapid remission of psychotic symptoms in schizophrenia and improved cognition in elderly patients. It acts as a 5-HT<sub>2A</sub> receptor agonist with modest selectivity for 5-HT<sub>1</sub>, exhibiting lower signaling potency than DOM. Notably, in a Parkinson’s disease model, Ariadne alleviated severe motor deficits comparable to l-DOPA, positioning it as a promising candidate for future psychiatric and neurological therapies.

Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.

ACS Chem Neurosci September 13, 2025 Emma M. Bonniwell, Rana Alabdali, Joseph J. Hennessey et al. 3 citations

The serotonin 2C receptor (5-HT 2C ) is involved in processes like mood and appetite and is a target for drugs treating obesity, addiction, and depression, including psychedelics. This analysis of 5-HT 2C signaling confirms that the receptor activates multiple G protein pathways—Gi/o/z and G12/13 in addition to its main Gq/11 pathway—and preferentially recruits β-arrestin2 over β-arrestin1. Increased RNA editing of the receptor reduces signaling across all G protein pathways, especially G12/13, while preserving β-arrestin recruitment. Profiling of ligands shows that psychedelics like LSD and psilocin produce a strong Gq/11 bias by minimally activating other G proteins. These findings provide a foundation for considering broader signaling modalities in 5-HT 2C drug development.